Effect of Bifilac Capsule in Recurrent Vaginitis infections

A Randomized open label study of Prebiotics and Probiotics (BIFILAC CAPSULE) in Recurrent Vaginitis as an add on therapy to Standard treatment - NIL

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/063844

Enrollment

100

Registered

2024-03-08

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N948- Other specified conditions associated with female genital organs and menstrual cycle

Interventions

Intervention1: Bifilac Capsule: Streptococcus faecalis T-110 JPC 30 million Clostridium butyricum TO-A 2 million Bacillus mesentericus TO-A JPC 1 million cell Lactobacillus sporogenes 50 million Con

Eligibility

Inclusion criteria

Inclusion criteria: Women aged 20 years to 58 years suffering from Recurrent vaginitis infections Patients willing to give a written informed consent

Exclusion criteria

Exclusion criteria: Pregnant and Lactating mother Not willing to give consent Patients with Sulfa drug allergy

Design outcomes

Primary

Measure	Time frame
Efficacy of Prebiotic and probiotic( Bifilac capsule) in reduction of symptoms in Recurrent vaginitis infection as an add on therapy to standard treatment. Recurrence rate in the recurrent vaginitis infectionTimepoint: 8 weeks + 4 months follow up for recurrence	—

Secondary

Measure	Time frame
Causative organism of recurrent vaginitis Change in vaginal pH in recurrent vaginitis patients by litmus paperTimepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDr Aruna

Government Kilpauk Medical College and Hospital

poovithapraba@gmail.com9841230508

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026